Answers are grounded in this paper and cite their sources.
Experimental study reveals high-affinity CAR signaling drives an inflammatory switch in human regulatory T cells, suggesting tailored receptor affinity improves therapeutic stability.
CAR Tregs uniquely acquiring CD40L surface expression and producing IFN-γ. Interestingly, decreasing CAR antigen affinity reduced Teff cell gene expression and inflammatory cytokine production by CAR Tregs. Our findings showcase the impact of engineered receptor activation on Treg biology and support tailoring CAR constructs to Tregs for maximal therapeutic efficacy.
No takes yet. Share an insight, caveat, or question.
Cochrane et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: